Novavax BA.1 booster data support COVID-19 vaccine strain switch, but bivalent fails to bring benefits

Novavax has generated phase 3 data to support a switch to its BA.1 variant COVID-19 vaccine. But with the original shot holding its own, and a bivalent version failing to bring benefits, the biotech is pushing the message that its existing adjuvanted recombinant protein vaccine remains viable.